Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

agitation

- PMLiVE

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

The FDA said there was not enough trial data from patients who were treated for at least a year

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

BioXcel Therapeutics doses first patient in phase 3 Alzheimer’s-associated agitation trial

Around 100 million agitation episodes are reported in the US each year in Alzheimer’s patients

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

- PMLiVE

New study links hearing restorative devices to slower rate of memory decline

The use of hearing aids and cochlear implants reduced long-term cognitive decline by 19%

- PMLiVE

Lilly’s donanemab shows promise in early symptomatic Alzheimer’s comparator study

Brain amyloid clearance was achieved in 37.9% of patients treated with the investigational antibody

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

New study links antioxidant flavonols to slower rate of memory decline

Flavonols are found naturally in fruits, vegetables and in plant products

- PMLiVE

New evidence review uncovers ‘significant’ link between particulate matter and dementia

Information from 17 existing studies was reviewed, involving 91 million people

- PMLiVE

Longitude Prize on Dementia launches innovator hackathons to those aiming for £1m grand prize

The prize will award a total of £4.34m for technology-based tool for people living with dementia

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

New study links omega-3 intake in midlife to reduced dementia risk

Over 2,000 people who did not have dementia or stroke took part in the study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links